The pathogenesis and management of disseminated intravascular coagulation

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 12, 2006, Pages 919-926

  Saba, Hussain I ^a,b,c   Morelli, Genevieve A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Consumptive coagulopathy; Disseminated intravascular coagulation; Hypercoagulable states

Indexed keywords

ACTIVATED PROTEIN C; ALTEPLASE; AMINOCAPROIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR; CYTOKINE; FIBRINOGEN; FRESH FROZEN PLASMA; GABEXATE MESILATE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTEIN C; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RETINOIC ACID; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TRANEXAMIC ACID;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CRYOPRECIPITATE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MECHANISM; DRUG MEGADOSE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GRAM NEGATIVE SEPSIS; HUMAN; HYPERCOAGULABILITY; HYPOXEMIA; LOW DRUG DOSE; MICROVASCULATURE; MORTALITY; PATHOGENESIS; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; RISK REDUCTION; SUBSTITUTION THERAPY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOSIS;

ANTICOAGULANTS; CYTOKINES; DISEASE PROGRESSION; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRINOLYSIS; HUMANS;

EID: 33846416920     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation, clinical and pathophysiological mechanisms and manifestations. Haemostasis. 1999;29 (2-3):111-134.
2. Saba HI. Disseminated intravascular coagulation (DIG). In Hematology Today: 2005. ed. M.B. Agarwal, 137-147.
3. Bakhshi S, Arya LS. Diagnosis and treatment of disseminated intravascular coagulation. Indian Pediatrics. 2003;40:721-730.
4. Zeeleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128:2864-2875.
5. Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med. 1983;107:543-547.
6. Mammen EF. Disseminated intravascular coagulation (DIG). Clin Lab Sci 2000;13:239-245.
7. Hambleton J, Leung LL, Levi M. Coagulation: Consultative Hemostasis. American Society of Hematology Educational Book. 2002:335-352.
8. Gilbert JA, Scalzi RP. Disseminated intravascular coagulation. Emerg Med Clin North Am. 1993;11:465-480.
9. Marwaha RK, Mitra S, Marwaha N. Disseminated intravascular coagulation: pathophysiology and principles of management. Indian Pediatr. 1998;35: 243-251.
10. Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thrombosis J. 2006;4:4-9.
11. Levi M. Disseminated intravascular coagulation: what's new? Crit Care Clin. 2005;21:449-467.
12. Van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Lack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, flbrinolytic and complement pathways. Blood 1990;76:2520-2526.
13. Taylor FBJ, Chang A, Ruf W, et al. Lethal E. Coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circulatory Shock. 1991; 33:127-134.
14. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by monoclonal anti-tissue factor antibody in chimpanzees. Journal of Clin Invest. 1994;93:114-120.
15. Levi M, ten Cate H. Disseminated intravascular coagulation. New Engl J Med. 1999;341:586-592.
16. Berckmans RJ, Nieuwland R, Romijn FR, Hack CE, Stutk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639-646.
17. Levi M. Current understanding of disseminated intravascular coagulation. Brit J Haematol. 2004;124:567-576.
18. Jochum M, Lander S, Heimburger N, Fritz H. Effect of human granulocytic elastase on isolated human antithrombin III. Hoppe Seylers Z Physiol Chem. 1981;362:103-112.
19. Jordan RE, Nelson RM, Kilpatrick J, Newgren JO, Esmon PC, Fournel MA. Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction. J Biol Chem. 1989;264:10493-10500.
20. Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithtombin III and plasma substitution. Eur J Haematol. 1989;43:22-28.
21. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;165:740-745.
22. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Molecular and Cellular Biol. 1988;8:5588-5592.
23. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med. 2001;29:590-594.
24. Biemond BJ, Levi M, van ten Cate H, Bullet HR, Hack CE, ten Cate JW. Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Science. 1995;88:587-594.
25. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemostas. 1996;75:902-907.
26. Westendorp RC, Hottenga JJ, Slagboon PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet. 1999;354: 561-563.
27. Grey ST, Tauchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma or phorbol ester. J Immunol. 1994:153:3664-3672.
28. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thrombo Haemostas. 2002;88:267-273.
29. Peters KA, Triolo PT, Darden DL. Disseminated intravascular coagulopathy: manifestations after a routine dental extraction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:419-23.
30. Herold J, Falworth MA. Disseminated intravascular coagulopathy presenting as a bleeding tooth socket. Br Dent J. 1994;177:21-22.
31. Zappoli FA, Brizio L, Alfonso C, Laus M. Disseminated intravascular coagulation during total hip replacement. Chir Organi Mov. 2002;87:125-131.
32. Bollapragada SS, Garg M, McFarlane T. Postmenopausal bleeding due to chronic DIC. Eur J Obstet Gynecol Reprod Biol. 2004;112:117-118.
33. Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost. 2001;27:593-604.
34. Ammon R, Walavalkar J, Gambert SR. Acquired bleeding disorders in the long-term care setting. Annals of Long-Term Care. 1998;6:242.
35. Karnad DR, Vasani J. Disseminated intravascular coagulation: A review with experience from an intensive care unit in India. J Postgrad Med. 1992; 38:186-193.
36. Levi M, de Jonge E, van der Poll T, ten Cate H. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thrombo Hemost. 2001;27:569-575.
37. Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thrombo Hemost. 2001;27:657-666.
38. Gupta PK, Gupta M, Chatterjee T, Saxena R. Comparative evaluation of whole Blood d-dimer test to plasma d-dimer test for diagnosis of disseminated intravascular coagulation. Indian J Exp Biol. 2005;43:382-384.
39. Bick RL, Baker WF. Diagnostic efficacy of the d-dimer assay in disseminated intravascular coagulation. Thromb Res. 1992;65:785-790.
40. Mugler K, Lefkowitz JB. False-positive D-dimer result in a patient with Castleman disease. Arch Path Lab Med. 2004;128:328-331.
41. Yu M, Nardella A, Pechet L. Screening tests for disseminated intravascular coagulation: Guidelines for rapid and specific laboratory diagnosis. Crit Care Med. 2000;28:1777-1780.
42. Wada H, Sase T, Yamaguchi M. Hypercoagulant states in malignant Lymphoma. Exp Oncol. 2005;27:179-185.
43. Bick RL. Disseminated intravascular coagulation: Objective criteria for clinical and laboratory diagnosis and assessment of response. Clin Appl Thrombosis/Hemostasis. 1995;1:3-23.
44. Levi M. Disseminated Intravascular Coagulation: New diagnostic criteria and supportive treatment strategies. 47th Scientific Committee Meeting of the International Society on Thrombosis and Haemostasis, July 6-7, 2001. Pari Medscape Cardiology 2001. Available online at: www.medscape.com. Accessed July 19, 2005.
45. Taylor FB Jr, Toh CH, Goots K, et al; for the Scientific Subcommittee on Disseminated Intravascular Coagulation. Towards a definition, clinical and laboratory criteria and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327-1330.
46. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004:3:2416-2421.
47. Sivula M, Tellgren M, Pettila V. Modified score for disseminated intravascular coagulation in the critically ill. Intensive Care Med. 2005;Jun 15 [epub ahead of print, accessed July 19, 2005]
48. Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2005;16:69-74.
49. Kobayashi N, Maegawa T, Takada M, et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the rResearch Committee on DIC in Japan. Bibl Haematol. 1983;49:265-275.
50. Gando S, Wada H, Asakura H, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thrombosis/Hemostasis. 2005;11:71-76.
51. Marder VJ, Martin SE, Colman RW. Clinical aspects of consumptive thrombohemorrhagic disorders. In: Colman RW, Hirsh J, Marder WJ, Salzman EW. Eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 1998:665.
52. Seligsohn U. Disseminated intravascular coagulation. In: Buetler E, Coller BS, Lichtman MA, Kipps TJ, Seligsohn U, eds. Williams Hematology Sixth Edition. 2001:1677-1695.
53. Kruger D. Acute systemic disseminated intravascular coagulation: Managing a complex medical condition. JAAPA. 2006;19:28-32.
54. Song JW, Choi JR, Song KS, Rhee JH. Plasma factor XIII activity in patients with disseminated intravascular coagulation. Yonsei Med. J 2006;47: 196-200.
55. Ten Cate H. Thrombocytopenia: One of the markers of disseminated intravascular coagulation. Pathophysiol Haemost Thromb. 2003/ 2004;33:413-416.
56. Toh CH, Dennis M. Disseminated intravascular coagulation: Old disease, new hope. Br Med J 2003;37:974-977.
57. Mant MJ, King EG. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. Am J Med. 1979;557-563.
58. Kessler CM, Nussbaum E, Tuazon CU. Disseminated intravascular coagulation associated with Staphylococcus aureus septicemia is mediated by peptidoglycan-induced platelet aggregation. J Infect Dis. 1991;164:101-107.
59. Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol. 2004;41:10-14.
60. Osborne WL, Lennard AL. Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to alemtuzumab (Campath 1H) or fludarabine. Haematologica. 2005;90:ERC05.
61. Zappoli PA, Brizio L, Alfonso C. Laus M. Disseminated intravascular coagulation during total hip replacement. Chir Organi Mov. 2002;87:125-131.
62. Falanga A, Rickles ER. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16: 463-482.
63. Feinstein DI. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. Blood. 1982;60: 284-287.
64. Seligsohn U. Disseminated intravascular coagulation. In: Buetler E, Coller BS, Lichtman MA, Kipps TJ, Seligsohn U, eds. Williams Hematology Sixth Edition. 2001:1677-1695.
65. Mant MJ, King EG. Severe, acute disseminated intravascular coagulation. A reappraisal of its pathophysiology, clinical significance and therapy based on 47 patients. Am J Med. 1979;67:557-563.
66. Warren BL, Eid A, Sainger P, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-1878.
67. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose anti-thrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemostas. 2006;4:90-97.
68. Alving BM, Spivak JL, DeLoughery TG. Consultative hematology: hemostasis and transfusion issues in surgery and critical care medicine. In: McArthur JR, Schechter GP, Schrier SL, eds. Hematology 1998: The American Society of Hematology Education Program Book. 1998:320-341.
69. Wiel E, Vallet B. A definite role for treatment with activated protein C in sepsis. J Thrombo Haemost. 2003;1:2466-2468.
70. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
71. Aoki N, Matsuda T, Saito H, Takatsuki K, et al. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int J Hematol. 2002;75: 540-547.
72. Abraham E. Tissue factor Inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 2000;28:S31-33.
73. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of a recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med. 2001;29:2081-2089.
74. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA. 2003;290:238-247.
75. Bick RL. Disseminated intravascular coagulation: Objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response. Semin Thromb Haemostasis. 1996;22:69-88.
76. Avvisati G, Buller HR, ten Gate JW, Mandell F. Transexamic acid for control of hemorrhage in acute promyelocytic leukemia. Lancet.1989;338:122-124.
77. LaBelle CA, Kitchens CS. Disseminated Intravascular Coagulation: Treat the cause, not the lab values. Cleveland Clinic J Med. 2005;72:377-397.
78. Wada H, Sakakura M, Kushiya F, et A. Thrombomodulin accelerates protein C production and inhibits thrombin generation in the plasma of disseminated intravascular coagulation patients. Blood Coagul Fibrinolysis. 2005;16:17-24.
79. Sallah S, Husain A, Nguyen NP. Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2004;15:577-582.
80. Martinez J, Cid AR, de la Rubia J, Gimero R. Treatment of intra-abdominal bleeding with recombinant activated factor VII in a patient with disseminated intravascular coagulation secondary to septic shock. Blood Coagul Fibrinolysis. 2005;16:297-299.
81. Roberts HR, Monroe DM 3rd, Hoffman M. Safety Profile of recombinant factor VIIa. Semin Hematol. 2004;41:101-108.
82. Taenaka N, Shimada Y, Hirata T, et al. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med. 1983; 11:735-738.
83. Umeki S, Adachi M, Watanabe M, et al. Gabexate as a therapy for disseminated intravascular coagulation. Arch Int Med. 1988;148:1409-1412.
84. Saito M, Asakura H, Jokaji H, et al. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with hematological malignancy. Blood Coagul Fibrinolysis. 1995;6:60-64.